

# Richard J Caselli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/375224/publications.pdf>

Version: 2024-02-01

140  
papers

10,706  
citations

50276

46  
h-index

33894

99  
g-index

149  
all docs

149  
docs citations

149  
times ranked

11706  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrating Transcriptomics, Genomics, and Imaging in Alzheimer's Disease: A Federated Model. <i>Frontiers in Radiology</i> , 2022, 1, .	2.0	1
2	Studying APOE $\epsilon$ 4 Allele Dose Effects with $\Delta$ Univariate Morphometry Biomarker. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1233-1250.	2.6	1
3	Developing univariate neurodegeneration biomarkers with low-rank and sparse subspace decomposition. <i>Medical Image Analysis</i> , 2021, 67, 101877.	11.6	10
4	DNA Methylation and Expression Profiles of Whole Blood in Parkinson's Disease. <i>Frontiers in Genetics</i> , 2021, 12, 640266.	2.3	33
5	Improved Prediction of Imminent Progression to Clinically Significant Memory Decline Using Surface Multivariate Morphometry Statistics and Sparse Coding. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 209-220.	2.6	6
6	Predicting future cognitive decline with hyperbolic stochastic coding. <i>Medical Image Analysis</i> , 2021, 70, 102009.	11.6	2
7	Plasma Apolipoprotein E3 and Glucose Levels Are Associated in APOE $\epsilon$ 3/ $\epsilon$ 4 Carriers. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 339-354.	2.6	13
8	Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases. <i>Frontiers in Neuroscience</i> , 2021, 15, 669595.	2.8	15
9	Multi-Resemblance Multi-Target Low-Rank Coding for Prediction of Cognitive Decline With Longitudinal Brain Images. <i>IEEE Transactions on Medical Imaging</i> , 2021, 40, 2030-2041.	8.9	6
10	Federated Morphometry Feature Selection for Hippocampal Morphometry Associated Beta-Amyloid and Tau Pathology. <i>Frontiers in Neuroscience</i> , 2021, 15, 762458.	2.8	5
11	Predicting Tau accumulation in cerebral cortex with multivariate MRI morphometry measurements, sparse coding, and correntropy. , 2021, 12088, .		1
12	Impact of Zumba on Cognition and Quality of Life is Independent of APOE4 Carrier Status in Cognitively Unimpaired Older Women: A 6-Month Randomized Controlled Pilot Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2020, 35, 153331751986837.	1.9	10
13	Brain imaging measurements of fibrillar amyloid $\beta$ burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the <i>APOE <math>\mu</math>4</i> allele. <i>Alzheimer's and Dementia</i> , 2020, 16, 598-609.	0.8	23
14	Neuropsychological decline up to 20 years before incident mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, 512-523.	0.8	37
15	Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 721-734.	2.6	11
16	Applying surface-based morphometry to study ventricular abnormalities of cognitively unimpaired subjects prior to clinically significant memory decline. <i>NeuroImage: Clinical</i> , 2020, 27, 102338.	2.7	18
17	Integrating Convolutional Neural Networks and Multi-Task Dictionary Learning for Cognitive Decline Prediction with Longitudinal Images. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 971-992.	2.6	9
18	Effect of ApoE isoforms on mitochondria in Alzheimer disease. <i>Neurology</i> , 2020, 94, e2404-e2411.	1.1	71

#	ARTICLE	IF	CITATIONS
19	An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis. <i>Alzheimer's and Dementia</i> , 2020, 16, 1582-1590.	0.8	18
20	Preliminary Assessment of Intravoxel Incoherent Motion <sc>Diffusion-Weighted MRI</sc> (<sc>IVIM&DWI</sc>) Metrics in Alzheimer's Disease. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 1811-1826.	3.4	30
21	APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. <i>Nature</i> , 2020, 581, 71-76.	27.8	705
22	Computing Univariate Neurodegenerative Biomarkers with Volumetric Optimal Transportation: A Pilot Study. <i>Neuroinformatics</i> , 2020, 18, 531-548.	2.8	3
23	Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia. <i>PLoS ONE</i> , 2020, 15, e0231720.	2.5	27
24	Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. <i>PLoS ONE</i> , 2019, 14, e0217566.	2.5	31
25	Applying surface-based hippocampal morphometry to study APOE-E4 allele dose effects in cognitively unimpaired subjects. <i>NeuroImage: Clinical</i> , 2019, 22, 101744.	2.7	40
26	Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age. <i>Nature Communications</i> , 2019, 10, 1619.	12.8	144
27	Genome-wide analyses as part of the international FTL-DTP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTL. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	7.7	90
28	Unbalanced Sample Size Introduces Spurious Correlations to Genome-Wide Heterozygosity Analyses. <i>Human Heredity</i> , 2019, 84, 197-202.	0.8	2
29	A concise and persistent feature to study brain resting-state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative. <i>Human Brain Mapping</i> , 2019, 40, 1062-1081.	3.6	26
30	Brain-Derived Neurotrophic Factor and Its Associations with Metabolism and Physical Activity in a Latino Sample. <i>Metabolic Syndrome and Related Disorders</i> , 2019, 17, 75-80.	1.3	6
31	Reply to Comment on "Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment". <i>Journal of the American Geriatrics Society</i> , 2019, 67, 192-193.	2.6	0
32	Multi-task Dictionary Learning Based on Convolutional Neural Networks for Longitudinal Clinical Score Predictions in Alzheimer's Disease. <i>Communications in Computer and Information Science</i> , 2019, 1072, 21-35.	0.5	5
33	Anticholinergic Medications and Cognitive Function in Late Midlife. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 262-264.	1.3	6
34	Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 671-678.	2.6	46
35	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	10.2	97
36	Amyloid- $\beta^2$ Increases Tau by Mediating Sirtuin 3 in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 8592-8601.	4.0	59

#	ARTICLE	IF	CITATIONS
37	Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimer's Disease Related Brain Regions. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 833-840.	2.6	7
38	P4080: SUBJECTIVE COGNITIVE IMPAIRMENT AND THE BROAD AUTISM PHENOTYPE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1466.	0.8	0
39	P3098: REDUCED GENOMIC DIVERSITY AS A RISK FACTOR FOR NONFAMILIAL YOUNG ONSET ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1104.	0.8	0
40	Age stratification corrects bias in estimated hazard of <i>APOE</i> genotype for Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 602-608.	3.7	20
41	Isometry Invariant Shape Descriptors for Abnormality Detection on Brain Surfaces Affected by Alzheimer's Disease. , 2018, 2018, 427-4631.		0
42	Neuropsychological comparison of incident MCI and prevalent MCI. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 599-603.	2.4	3
43	<i>APOE</i> $\epsilon$ 2 is associated with increased tau pathology in primary tauopathy. <i>Nature Communications</i> , 2018, 9, 4388.	12.8	100
44	At the Intersection of Patient Experience Data, Outcomes Research, and Practice: Analysis of HCAHPS Scores in Neurology Patients. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2018, 2, 137-147.	2.4	7
45	Replication of progressive supranuclear palsy genome-wide association study identifies <i>SLCO1A2</i> and <i>DUSP10</i> as new susceptibility loci. <i>Molecular Neurodegeneration</i> , 2018, 13, 37.	10.8	54
46	Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 603-615.	2.6	12
47	Multi-task sparse screening for predicting future clinical scores using longitudinal cortical thickness measures. , 2018, 2018, 1406-1410.		7
48	Subjective Cognitive Impairment and the Broad Autism Phenotype. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 284-290.	1.3	7
49	Bi-threshold frequent subgraph mining for Alzheimer disease risk assessment. , 2018, , .		0
50	Sex and post-menopause hormone therapy effects on hippocampal volume and verbal memory. <i>Aging, Neuropsychology, and Cognition</i> , 2017, 24, 227-246.	1.3	18
51	A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, nlw105.	1.7	23
52	Peripheral apoE isoform levels in cognitively normal <i>APOE</i> $\epsilon$ 3/ $\epsilon$ 4 individuals are associated with regional gray matter volume and cerebral glucose metabolism. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 5.	6.2	29
53	Alzheimer Disease. <i>Mayo Clinic Proceedings</i> , 2017, 92, 978-994.	3.0	57
54	Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 23-35.	2.6	23

#	ARTICLE	IF	CITATIONS
55	Conformal invariants for multiply connected surfaces: Application to landmark curve-based brain morphometry analysis. <i>Medical Image Analysis</i> , 2017, 35, 517-529.	11.6	9
56	[O1â€“12â€“02]: PROGRESSION FROM PRECLINICAL AD TO MCI OVER A DECADE: COGNITIVE AND BRAIN IMAGING TRAJECTORIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P222.	0.8	0
57	Deep-learning-based classification of FDG-PET data for Alzheimer's disease categories. , 2017, 10572, .		28
58	Multi-source Multi-target Dictionary Learning for Prediction of Cognitive Decline. <i>Lecture Notes in Computer Science</i> , 2017, 10265, 184-197.	1.3	15
59	Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 271-277.	1.3	3
60	Influence of APOE Genotype on Hippocampal Atrophy over Time - An N=1925 Surface-Based ADNI Study. <i>PLoS ONE</i> , 2016, 11, e0152901.	2.5	59
61	Impact of Personality on Cognitive Aging: A Prospective Cohort Study. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 765-776.	1.8	40
62	Morphometric analysis of hippocampus and lateral ventricle reveals regional difference between cognitively stable and declining persons. , 2016, 2016, 14-18.		5
63	Hyperbolic Space Sparse Coding with Its Application on Prediction of Alzheimerâ€™s Disease in Mild Cognitive Impairment. <i>Lecture Notes in Computer Science</i> , 2016, 9900, 326-334.	1.3	17
64	Clinical Impact of Amyloid Positron Emission Tomographyâ€™Is It Worth the Cost?. <i>JAMA Neurology</i> , 2016, 73, 1396.	9.0	11
65	Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 748-754.	1.7	82
66	Predictive Testing for Alzheimerâ€™s Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 252-254.	1.3	15
67	Sex-Based Memory Advantages and Cognitive Aging: A Challenge to the Cognitive Reserve Construct?. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 95-104.	1.8	29
68	Association of Pituitary Adenylate Cyclaseâ€“Activating Polypeptide With Cognitive Decline in Mild Cognitive Impairment Due to Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 333.	9.0	48
69	<sc>A</sc>rizona <sc>S</sc>tudy of <sc>A</sc>ging and <sc>N</sc>eurodegenerative <sc>D</sc>isorders and <sc>B</sc>rain and <sc>B</sc>ody <sc>D</sc>onation <sc>P</sc>rogram. <i>Neuropathology</i> , 2015, 35, 354-389.	1.2	336
70	A novel cortical thickness estimation method based on volumetric Laplaceâ€“Beltrami operator and heat kernel. <i>Medical Image Analysis</i> , 2015, 22, 1-20.	11.6	23
71	APOE Î¼4 Genotype and the Risk for Subjective Cognitive Impairment in Elderly Persons. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, 322-325.	1.8	10
72	Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment. <i>BMC Neurology</i> , 2015, 15, 146.	1.8	36

#	ARTICLE	IF	CITATIONS
73	Characterizing Apolipoprotein E $\epsilon$ 4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal $\beta$ -Amyloid Peptide Plaques. <i>JAMA Neurology</i> , 2015, 72, 1124.	9.0	78
74	Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometry. <i>NeuroImage</i> , 2015, 104, 1-20.	4.2	42
75	Pituitary adenylate cyclase-activating polypeptide is reduced in Alzheimer disease. <i>Neurology</i> , 2014, 82, 1724-1728.	1.1	53
76	Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1739-1742.	1.5	4
77	The neuropsychology of normal aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 84-92.	0.8	55
78	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. <i>Neurobiology of Aging</i> , 2014, 35, 2421.e13-2421.e17.	3.1	74
79	Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools?. <i>Alzheimer's and Dementia</i> , 2014, 10, 853-860.	0.8	73
80	Public Perceptions of Presymptomatic Testing for Alzheimer Disease. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1389-1396.	3.0	55
81	Fibrillar amyloid correlates of preclinical cognitive decline. , 2014, 10, e1-e8.		15
82	Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An $n = 725$ surface-based Alzheimer's disease neuroimaging initiative study. <i>Human Brain Mapping</i> , 2014, 35, 3903-3918.	3.6	62
83	Genomic Medicine and Incidental Findings: Balancing Actionability and Patient Autonomy. <i>Mayo Clinic Proceedings</i> , 2014, 89, 718-721.	3.0	15
84	Subjective cognitive decline: Self and informant comparisons. <i>Alzheimer's and Dementia</i> , 2014, 10, 93-98.	0.8	111
85	P2-356: PREDICTIVE TESTING FOR ALZHEIMER'S DISEASE: SUICIDAL IDEATION AMONG HEALTHY PARTICIPANTS. <i>Alzheimer's and Dementia</i> , 2014, 10, P610.	0.8	2
86	O4-12-02: SHORT-TERM MEMORY BINDING IN PRESYMPTOMATIC APOE E4 CARRIERS. , 2014, 10, P275-P276.		0
87	Ushering in the study and treatment of preclinical Alzheimer disease. <i>Nature Reviews Neurology</i> , 2013, 9, 371-381.	10.1	125
88	O3-12-01: An Internet-based survey assessing public attitudes about preclinical testing for Alzheimer's disease. , 2013, 9, P545-P546.		0
89	Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. <i>Neurology</i> , 2013, 80, 1557-1564.	1.1	83
90	Posterior Cingulate Glucose Metabolism, Hippocampal Glucose Metabolism, and Hippocampal Volume in Cognitively Normal, Late-Middle-Aged Persons at 3 Levels of Genetic Risk for Alzheimer Disease. <i>JAMA Neurology</i> , 2013, 70, 320.	9.0	123

#	ARTICLE	IF	CITATIONS
91	Apolipoprotein E as a $\beta$ -amyloid-independent factor in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 38.	6.2	48
92	Depressive Symptoms in Healthy Apolipoprotein E $\epsilon$ 4 Carriers and Noncarriers. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 1256-1261.	2.2	24
93	Association between an Alzheimer's Disease-Related Index and APOE $\epsilon$ 4 Gene Dose. <i>PLoS ONE</i> , 2013, 8, e67163.	2.5	13
94	Longitudinal modeling of cognitive aging and the TOMM40 effect. <i>Alzheimer's and Dementia</i> , 2012, 8, 490-495.	0.8	61
95	Phenotypic differences between apolipoprotein E genetic subgroups: research and clinical implications. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 20.	6.2	7
96	Characterizing the Preclinical Stages of Alzheimer's Disease and the Prospect of Presymptomatic Intervention. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S405-S416.	2.6	73
97	Gray matter network associated with risk for Alzheimer's disease in young to middle-aged adults. <i>Neurobiology of Aging</i> , 2012, 33, 2723-2732.	3.1	81
98	Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E $\epsilon$ 4 gene dose in cognitively normal adults: A cross-validation study using voxel-based multi-modal partial least squares. <i>NeuroImage</i> , 2012, 60, 2316-2322.	4.2	36
99	Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. <i>Neurodegenerative Disease Management</i> , 2012, 2, 183-195.	2.2	20
100	Correlates of quitting the Paced Auditory Serial Addition Test in cognitively normal older adults participating in a study of normal cognitive aging. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2011, 33, 937-943.	1.3	3
101	Anxiety Affects Cognition Differently in Healthy Apolipoprotein E $\epsilon$ 4 Homozygotes and Non-Carriers. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 294-299.	1.8	9
102	Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 321-329.	2.6	309
103	Reduced Posterior Cingulate Mitochondrial Activity in Expired Young Adult Carriers of the APOE $\epsilon$ 4 Allele, the Major Late-Onset Alzheimer's Susceptibility Gene. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 307-313.	2.6	131
104	APOE $\epsilon$ 2 and presymptomatic stage Alzheimer disease. <i>Neurology</i> , 2010, 75, 1952-1953.	1.1	5
105	Hypometabolism in Alzheimer-Affected Brain Regions in Cognitively Healthy Latino Individuals Carrying the Apolipoprotein E $\epsilon$ 4 Allele. <i>Archives of Neurology</i> , 2010, 67, 462-8.	4.5	89
106	Amyloid load in nondemented brains correlates with APOE $\epsilon$ 4. <i>Neuroscience Letters</i> , 2010, 473, 168-171.	2.1	76
107	Fibrillar amyloid- $\beta$ burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6820-6825.	7.1	700
108	Assessment of Patient and Caregiver Experiences of Dementia-Related Symptoms: Development of the Multidimensional Assessment of Neurodegenerative Symptoms Questionnaire. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 260-272.	1.5	9

#	ARTICLE	IF	CITATIONS
109	Longitudinal Modeling of Age-Related Memory Decline and the <i>APOE</i> $\epsilon$ 4 Effect. <i>New England Journal of Medicine</i> , 2009, 361, 255-263.	27.0	469
110	Creativity. <i>Cognitive and Behavioral Neurology</i> , 2009, 22, 143-154.	0.9	8
111	Double-Blind Crossover Study of the Cognitive Effects of Lorazepam in Healthy Apolipoprotein E ( <i>APOE</i> ) $\epsilon$ 4 Carriers. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1379-1384.	2.2	23
112	Age-related memory decline and apolipoprotein E $\epsilon$ 4. <i>Discovery Medicine</i> , 2009, 8, 47-50.	0.5	5
113	Obstructive sleep apnea, apolipoprotein E $\epsilon$ 4, and mild cognitive impairment. <i>Sleep Medicine</i> , 2008, 9, 816-817.	1.6	16
114	Medical Management of Frontotemporal Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2008, 22, 489-498.	1.9	13
115	Correlating Cerebral Hypometabolism With Future Memory Decline in Subsequent Converters to Amnestic Pre- $\epsilon$ 4 Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2008, 65, 1231-6.	4.5	91
116	Cognitive Performance in Older Women Relative to ApoE $\epsilon$ 4 Genotype and Aerobic Fitness. <i>Medicine and Science in Sports and Exercise</i> , 2007, 39, 199-207.	0.4	103
117	Cognitive Domain Decline in Healthy Apolipoprotein E $\epsilon$ 4 Homozygotes Before the Diagnosis of Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1306.	4.5	137
118	Correlations Between Apolipoprotein E $\epsilon$ 4 Gene Dose and Whole Brain Atrophy Rates. <i>American Journal of Psychiatry</i> , 2007, 164, 916-921.	7.2	104
119	GAB2 Alleles Modify Alzheimer's Risk in <i>APOE</i> $\epsilon$ 4 Carriers. <i>Neuron</i> , 2007, 54, 713-720.	8.1	451
120	Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms. <i>American Journal of Human Genetics</i> , 2007, 80, 769-778.	6.2	68
121	The Degenerative Dementias. , 2007, , 699-733.		4
122	Common <i>Kibra</i> Alleles Are Associated with Human Memory Performance. <i>Science</i> , 2006, 314, 475-478.	12.6	391
123	A Preliminary Fluorodeoxyglucose Positron Emission Tomography Study in Healthy Adults Reporting Dream-Enactment Behavior. <i>Sleep</i> , 2006, 29, 927-933.	1.1	51
124	Alzheimer's Disease A Century Later. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1784-1800.	2.2	99
125	Correlations between apolipoprotein E $\epsilon$ 4 gene dose and brain-imaging measurements of regional hypometabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8299-8302.	7.1	366
126	Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 284-289.	7.1	907



#	ARTICLE	IF	CITATIONS
127	A Distinctive Interaction Between Chronic Anxiety and Problem Solving in Asymptomatic APOE e4 Homozygotes. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2004, 16, 320-329.	1.8	39
128	Apolipoprotein E $\epsilon$ 4 affects new learning in cognitively normal individuals at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 947-952.	3.1	66
129	Current Issues in the Diagnosis and Management of Dementia. <i>Seminars in Neurology</i> , 2003, 23, 231-240.	1.4	15
130	Progressive Aphasia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 14, 55-58.	1.5	37
131	A Distinctive Interaction Between Memory and Chronic Daytime Somnolence in Asymptomatic APOE e4 Homozygotes. <i>Sleep</i> , 2002, 25, 437-443.	1.1	29
132	Apolipoprotein E and Intellectual Achievement. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 49-54.	2.6	13
133	A distinctive interaction between memory and chronic daytime somnolence in asymptomatic APOE e4 homozygotes. <i>Sleep</i> , 2002, 25, 447-53.	1.1	14
134	Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study. <i>Journal of the Neurological Sciences</i> , 2001, 189, 93-98.	0.6	57
135	Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease. <i>Clinical Neuroscience Research</i> , 2001, 1, 194-206.	0.8	26
136	Visual Syndromes as the Presenting Feature of Degenerative Brain Disease. <i>Seminars in Neurology</i> , 2000, Volume 20, 0139-0144.	1.4	23
137	A kinematic study of progressive apraxia with and without dementia. <i>Movement Disorders</i> , 1999, 14, 276-287.	3.9	20
138	Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. <i>Annals of Neurology</i> , 1998, 44, 288-291.	5.3	257
139	Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the $\epsilon$ 4 Allele for Apolipoprotein E. <i>New England Journal of Medicine</i> , 1996, 334, 752-758.	27.0	1,320
140	The treatable dementia of sjögren's syndrome. <i>Annals of Neurology</i> , 1991, 30, 98-101.	5.3	68